atai Life Sciences’ DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

March 10, 2021 Articles 8:00 am

DemeRx IB, Inc., an atai Life Sciences platform company focused on developing ibogaine for the treatment of opioid use disorder, today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency to commence subject enrolment in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002).

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit